Review anchor
Proto-oncogene tyrosine-protein kinase receptor Ret
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
Evidence Snapshot
Proto-oncogene tyrosine-protein kinase receptor Ret
CHEMBL2041
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Proto-oncogene tyrosine-protein kinase receptor Ret as ChEMBL target CHEMBL2041, mapped to UniProt P07949. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL2041
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P07949
Proto-oncogene tyrosine-protein kinase receptor Ret
UniProt accession via ChEMBL component mapping
As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-14
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Proto-oncogene tyrosine-protein kinase receptor Ret matters
Proto-oncogene tyrosine-protein kinase receptor Ret is reviewed as Proto-oncogene tyrosine-protein kinase receptor Ret (UniProt P07949); Proto-oncogene tyrosine-protein kinase receptor Ret shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block.; 9 linked drugs keep this evidence frame grounded.; the current evidence base includes 65 approved drugs, 6476 compounds, and 1417 assays, with lead potency reaching pChEMBL 10.8.
Protein context
Proto-oncogene tyrosine-protein kinase receptor Ret
Proto-oncogene tyrosine-protein kinase receptor Ret Sequence length is 1114 aa.
Review this target as Proto-oncogene tyrosine-protein kinase receptor Ret, mapped to UniProt P07949. Sequence length is 1114 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P07949
Protein
Disease context
neoplasm
Proto-oncogene tyrosine-protein kinase receptor Ret shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 9 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include CEP-32496, PRALSETINIB, QUIZARTINIB.
Start review with neoplasm because it currently carries approved-linked support. Linked drugs include CEP-32496, PRALSETINIB, QUIZARTINIB, REGORAFENIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
9 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 65 approved drugs, 6476 compounds, and 1417 assays for this target. The dominant activity type is IC50. CHEMBL5962713 is the current potency anchor at pChEMBL 10.8.
Use CHEMBL5962713 as the tractability anchor when discussing potency (pChEMBL 10.8).
Activity source · ChEMBL 36 via Core Engine
65 approved
pChEMBL 10.8
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Proto-oncogene tyrosine-protein kinase receptor Ret matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P07949, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why neoplasm is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
6476
Total Compounds
1417
Total Assays
65
Approved Drugs
IC50: 25018.0, KI: 749.0, EC50: 7.0, KD: 692.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL5962713
|
10.8 | IC50 | — |
|
|
No preferred name
CHEMBL4067871
|
10.4 | IC50 | — |
|
|
No preferred name
CHEMBL5944764
|
10.4 | IC50 | — |
|
|
No preferred name
CHEMBL5916213
|
10.2 | IC50 | — |
|
|
No preferred name
CHEMBL5838635
|
10.1 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
QUIZARTINIB
CHEMBL576982
|
2023 |
|
|
SELPERCATINIB
CHEMBL4559134
|
2020 |
|
|
PRALSETINIB
CHEMBL4582651
|
2020 |
|
|
FEDRATINIB
CHEMBL1287853
|
2019 |
|
|
ENTRECTINIB
CHEMBL1983268
|
2019 |
|
|
GILTERITINIB
CHEMBL3301622
|
2018 |
|
|
BRIGATINIB
CHEMBL3545311
|
2017 |
|
|
TIVOZANIB
CHEMBL1289494
|
2017 |
|
|
MIDOSTAURIN
CHEMBL608533
|
2017 |
|
|
BARICITINIB
CHEMBL2105759
|
2017 |
|
|
LENVATINIB
CHEMBL1289601
|
2015 |
|
|
ALECTINIB
CHEMBL1738797
|
2015 |
|
|
NINTEDANIB
CHEMBL502835
|
2014 |
|
|
CERITINIB
CHEMBL2403108
|
2014 |
|
|
IBRUTINIB
CHEMBL1873475
|
2013 |
|
|
CABOZANTINIB
CHEMBL2105717
|
2012 |
|
|
REGORAFENIB
CHEMBL1946170
|
2012 |
|
|
AXITINIB
CHEMBL1289926
|
2012 |
|
|
PONATINIB
CHEMBL1171837
|
2012 |
|
|
VEMURAFENIB
CHEMBL1229517
|
2011 |
|
|
VANDETANIB
CHEMBL24828
|
2011 |
|
|
RUXOLITINIB
CHEMBL1789941
|
2011 |
|
|
PAZOPANIB
CHEMBL477772
|
2009 |
|
|
NILOTINIB
CHEMBL255863
|
2007 |
|
|
SUNITINIB
CHEMBL535
|
2006 |
|
|
DASATINIB
CHEMBL5416410
|
2006 |
|
|
DASATINIB ANHYDROUS
CHEMBL1421
|
2006 |
|
|
SORAFENIB
CHEMBL1336
|
2005 |
|
|
ERLOTINIB
CHEMBL553
|
2004 |
|
|
CYCLOBENZAPRINE
CHEMBL669
|
1977 |
|
|
AMITRIPTYLINE
CHEMBL629
|
1961 |
Source Header